South Korea · Delayed Price · Currency is KRW John Keells Holdings Statistics
Total Valuation
Aminologics has a market cap or net worth of KRW 105.30 billion. The enterprise value is 53.82 billion.
| Market Cap | 105.30B |
| Enterprise Value | 53.82B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aminologics has 87.83 million shares outstanding. The number of shares has decreased by -1.26% in one year.
| Current Share Class | 87.83M |
| Shares Outstanding | 87.83M |
| Shares Change (YoY) | -1.26% |
| Shares Change (QoQ) | +1.28% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 0.17% |
| Float | 59.89M |
Valuation Ratios
The trailing PE ratio is 46.97.
| PE Ratio | 46.97 |
| Forward PE | n/a |
| PS Ratio | 4.64 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.91 |
| P/FCF Ratio | 13.94 |
| P/OCF Ratio | 13.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.83, with an EV/FCF ratio of 7.13.
| EV / Earnings | 23.83 |
| EV / Sales | 2.37 |
| EV / EBITDA | 12.83 |
| EV / EBIT | 14.50 |
| EV / FCF | 7.13 |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.29.
| Current Ratio | 2.75 |
| Quick Ratio | 2.47 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | 2.20 |
| Interest Coverage | 2.54 |
Financial Efficiency
Return on equity (ROE) is 4.05% and return on invested capital (ROIC) is 48.84%.
| Return on Equity (ROE) | 4.05% |
| Return on Assets (ROA) | 3.17% |
| Return on Invested Capital (ROIC) | 48.84% |
| Return on Capital Employed (ROCE) | 6.43% |
| Weighted Average Cost of Capital (WACC) | 7.50% |
| Revenue Per Employee | 566.90M |
| Profits Per Employee | 56.47M |
| Employee Count | 40 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 2.31 |
Taxes
In the past 12 months, Aminologics has paid 60.53 million in taxes.
| Income Tax | 60.53M |
| Effective Tax Rate | 2.61% |
Stock Price Statistics
The stock price has increased by +28.10% in the last 52 weeks. The beta is 0.56, so Aminologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +28.10% |
| 50-Day Moving Average | 1,354.76 |
| 200-Day Moving Average | 1,229.42 |
| Relative Strength Index (RSI) | 44.84 |
| Average Volume (20 Days) | 282,931 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aminologics had revenue of KRW 22.68 billion and earned 2.26 billion in profits. Earnings per share was 25.53.
| Revenue | 22.68B |
| Gross Profit | 10.21B |
| Operating Income | 3.71B |
| Pretax Income | 2.32B |
| Net Income | 2.26B |
| EBITDA | 4.20B |
| EBIT | 3.71B |
| Earnings Per Share (EPS) | 25.53 |
Balance Sheet
The company has 68.13 billion in cash and 16.64 billion in debt, with a net cash position of 51.49 billion or 586.22 per share.
| Cash & Cash Equivalents | 68.13B |
| Total Debt | 16.64B |
| Net Cash | 51.49B |
| Net Cash Per Share | 586.22 |
| Equity (Book Value) | 57.11B |
| Book Value Per Share | 642.11 |
| Working Capital | 52.30B |
Cash Flow
In the last 12 months, operating cash flow was 7.63 billion and capital expenditures -75.70 million, giving a free cash flow of 7.55 billion.
| Operating Cash Flow | 7.63B |
| Capital Expenditures | -75.70M |
| Depreciation & Amortization | 484.02M |
| Net Borrowing | 19.71B |
| Free Cash Flow | 7.55B |
| FCF Per Share | 85.99 |
Margins
Gross margin is 45.01%, with operating and profit margins of 16.37% and 9.96%.
| Gross Margin | 45.01% |
| Operating Margin | 16.37% |
| Pretax Margin | 10.23% |
| Profit Margin | 9.96% |
| EBITDA Margin | 18.50% |
| EBIT Margin | 16.37% |
| FCF Margin | 33.30% |
Dividends & Yields
Aminologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.26% |
| Shareholder Yield | 1.26% |
| Earnings Yield | 2.15% |
| FCF Yield | 7.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 23, 2009. It was a forward split with a ratio of 5.
| Last Split Date | Oct 23, 2009 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Aminologics has an Altman Z-Score of 1.96 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.96 |
| Piotroski F-Score | 6 |